Investing in Catalyst Biosciences, Inc. (CBIO)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)0.21Infinity
Intrinsic value (DCF)0.21Infinity
Graham-Dodd Method5.18Infinity
Graham Formula0.00NaN

Company description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.